Delcath Systems to Host July 27th Conference Call to Update Investors on Recent Progress

Tue Jul 14, 2009 6:30am EDT
 
[-] Text [+]
Delcath Systems to Host July 27th Conference Call to Update Investors on
Recent Progress



NEW YORK, July 14 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq:
DCTH) today announced that it will release financial results for the second
quarter ended June 30, 2009 on Monday, July 27, 2009 after the market close.
In addition, Eamonn Hobbs, the Company's new President & CEO will host a
conference call and webcast on Monday, July 27, 2009 at 4:30 p.m. Eastern /
1:30 p.m. Pacific to discuss the Company's recent progress.  The dial-in
number for the conference call is 877-941-0844 for domestic participants and
480-629-9645 for international participants.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO)

A taped replay of the conference call will also be available beginning
approximately one hour after the call's conclusion and will be available for
seven days.  This replay can be accessed by dialing 800-406-7325 for domestic
callers and 303-590-3030 for international callers, both using passcode
4117854#.  To access the live webcast of the call, go to Delcath's website at
www.delcath.com.  An archived webcast will also be available at
www.delcath.com. 

About Delcath Systems

Delcath Systems and its proprietary targeted drug delivery system are at the
forefront of the regional treatment of cancer. The Company's technology, known
as Percutaneous Hepatic Perfusion (PHP), allows physicians to deliver
significantly higher doses of anti-cancer drugs to the site of disease without
exposing the patient's entire body to those same potent levels of drug.
Initial clinical results from studies treating cancer in the liver confirm
that delivering more drug to the tumor site, and less to the other regions of
the body, enhances tumor shrinkage with improved quality of life over systemic
cancer therapies. PHP is currently undergoing testing in Phase III and Phase
II clinical trials for a variety of cancers of the liver. More information is
available at http://www.delcath.com. 

SOURCE  Delcath Systems, Inc.

Investors,, Doug Sherk, or Mike Pollak, +1-415-896-6820, or Stacey Fisher,
+1-305-335-9577, or Financial Media, Steve DiMattia, +1-646-201-5445, all of
EVC Group

 

Featured Broker sponsored link

Editor's Choice

A selection of our best photos from the past 24 hours.   Slideshow 

Most Popular on Reuters

  • Articles
  • Video